Quick Answer
Neumora Therapeutics, Inc. reported Net Income Loss of -$236.93 million for the year ending 2025.
- Neumora Therapeutics, Inc. showed an increase of +2.8% in Net Income Loss from 2024 to 2025.
- This data is from Neumora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$43.04 million | Q2 2022: -$30.37 million | Q3 2022: -$29.34 million | Q1 2023: -$35.63 million | Q2 2023: -$38.54 million | Q3 2023: -$53.03 million | Q1 2024: -$53.72 million | Q2 2024: -$58.70 million | Q3 2024: -$72.55 million | Q1 2025: -$67.99 million | Q2 2025: -$52.73 million | Q3 2025: -$56.76 million.
- Over the full 4 years of available data (2022 to 2025), Neumora Therapeutics, Inc.'s Net Income Loss has declined by 81.0%.
- Historical annual values: Fiscal year 2025: -$236.93 million | Fiscal year 2024: -$243.79 million | Fiscal year 2023: -$235.93 million | Fiscal year 2022: -$130.90 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: